WO2006059716A1 - 固形製剤 - Google Patents
固形製剤 Download PDFInfo
- Publication number
- WO2006059716A1 WO2006059716A1 PCT/JP2005/022187 JP2005022187W WO2006059716A1 WO 2006059716 A1 WO2006059716 A1 WO 2006059716A1 JP 2005022187 W JP2005022187 W JP 2005022187W WO 2006059716 A1 WO2006059716 A1 WO 2006059716A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- group
- substituted
- alkyl
- solid preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a solid preparation, and more particularly to a solid preparation containing a medicinal component that is easily gelled.
- a solid preparation containing such a medicinal ingredient has a markedly reduced rate of absorption of the medicinal ingredient into the body.
- the solid preparation disintegrates in the gastrointestinal tract, and the medicinal ingredient is eluted and absorbed into the body, whereas it contains a medicinal ingredient that easily gels.
- the disintegration of the solid preparation is prevented by the gelling of the medicinal component.
- An object of the present invention is to improve the disintegration property of a solid preparation containing a medicinal component that is easily gelled.
- the present invention relates to a solid preparation containing a medicinal ingredient that is easily gelled, It is a further object to improve the elution property of.
- Another object of the present invention is to improve manufacturability in a solid preparation with improved disintegration of the solid preparation.
- Another object of the present invention is to improve the stability of a solid preparation in which the disintegration property of the solid preparation is improved.
- the present invention is a.
- the salt is hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, succinic acid, succinic acid, malic acid, methanesulfone
- R 1 represents an optionally substituted 5- to 6-membered ring
- X 1 represents a divalent group having 1 to 4 atoms constituting a bond or a straight chain part, and ring A is substituted !, may! /, 5 !, and 6-membered ring Ring B is substituted !, may! /, Represents an 8- to 10-membered ring,
- E and E are each optionally substituted carbon atoms or optionally substituted Indicates a nitrogen atom,
- E and E are each an optionally substituted carbon atom and an optionally substituted nitrogen
- a and b are each a single bond or a double bond
- X 2 represents a divalent group having 1 to 4 atoms constituting the linear portion
- Z 1 represents a bond or a divalent cyclic group
- Z 2 represents a bond or a divalent group
- R 2 is (1) an amino group which may be substituted or substituted with a nuclear atomic grade ammonium or oxidized, and (2) a sulfur atom or oxygen as a ring atom which may be substituted.
- a nitrogen-containing heterocyclic group which may contain an atom and may be nitrogen-atom class ammomized or oxidized;
- k represents 0 or 1
- R 5 and R 6 may each be an optionally substituted hydrocarbon group.
- the disintegration property of the said solid formulation can be improved in the solid formulation containing the medicinal component which is easy to gelatinize.
- the elution property of the said solid formulation can be improved in the solid formulation containing the medicinal component which is easy to gelatinize.
- the solid preparation in the solid preparation with improved disintegration of the solid preparation, the solid preparation
- the manufacturability of the preparation can be improved.
- the stability of the said solid formulation can be improved in the solid formulation which improved the disintegration property of the solid formulation.
- Fig. 1 is a graph showing the elution rate of Compound A.
- the "medicinal ingredient easily gelled” refers to the presence of water, i.e., when exposed to water such as drinking water or body fluids such as saliva and gastric juice.
- a medicinal ingredient i.e., when exposed to water such as drinking water or body fluids such as saliva and gastric juice.
- Examples of the “easily gelled and glaze-effective ingredient” suitable for application of the present invention include salts of compounds that are free and extremely sparingly soluble.
- “super-poorly soluble” the compound is, upon administration to the living body, under any circumstances that may be exposed, 10 _3 mgZmL or less, preferably 10- 4MgZmL, more preferably 10 _5 mgZmL
- the property which shows the following solubility is said.
- its salt needs to exhibit higher solubility than its free form. The larger the difference in solubility between the two (for example, 1000 times, preferably 1000 times, more preferably 100000 times), the more the compound tends to gel.
- the solubility of the medicinal ingredient is determined by suspending 10 mg of the medicinal ingredient in 10 mL of purified water at 20 ° C, followed by filtration, and then analyzing the medicinal ingredient dissolved in the purified water by high performance liquid chromatography It can be determined by measuring the content.
- the salt include, for example, a salt with an inorganic base (for example, an alkali metal salt such as a sodium salt and a strong rhodium salt; an alkaline earth metal salt such as a calcium salt and a magnesium salt; and aluminum Salts, ammonium salts), organic bases (eg trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, N, -dibenzylethylenedi Salts with inorganic acids (eg hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid), organic acids (eg formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid) , Succinic acid, succinic acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid
- an inorganic base for
- Examples of the “medicinal ingredient that is easily gelled” are known compounds that are disclosed in, for example, International Publication 03Z055525 pamphlet and can be produced by the method described in the pamphlet.
- R 1 represents an optionally substituted 5- to 6-membered ring
- X 1 represents a divalent group having 1 to 4 atoms constituting a bond or a straight chain part, and ring A is substituted !, may! /, 5 !, and 6-membered ring Ring B is substituted !, may! /, Represents an 8- to 10-membered ring,
- E and E are each optionally substituted carbon atoms or optionally substituted
- E and E are each an optionally substituted carbon atom and an optionally substituted nitrogen
- a and b are each a single bond or a double bond
- X 2 represents a divalent group having 1 to 4 atoms constituting the linear portion
- Z 1 represents a bond or a divalent cyclic group
- Z 2 represents a bond or a divalent group
- R 2 is (1) an amino group which may be substituted or substituted with a nuclear atomic grade ammonium or oxidized, and (2) a sulfur atom or oxygen as a ring atom which may be substituted.
- a nitrogen-containing heterocyclic group which may contain an atom and may be nitrogen-atom class ammomized or oxidized;
- k represents 0 or 1
- R 5 and R 6 may each be an optionally substituted hydrocarbon group.
- the salt of the compound represented by this is mentioned.
- halogen in the present specification examples include fluorine, chlorine, bromine, and iodine.
- the “5- to 6-membered ring” of the “substituted or 5-membered ring group” represented by R 1 is a 6-membered aromatic carbonization such as benzene.
- 5- to 6-membered aliphatic hydrocarbons such as hydrogen, cyclopentane, cyclohexane, cyclopentene, cyclohexene, cyclopentanegen, cyclohexanegene, furan, thiophene, pyrrole, imidazole, pyrazole, thiazole, oxazole, iso
- Nitrogen atoms such as thiazole, isoxazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, triazole, sulfur atoms and oxygen atomic energy 5 to 6-membered aromatics containing 1 to 2 selected heteroatoms Heterocycle, tetrahydrofuran, tetrahydr
- Examples include groups formed by removing one force hydrogen atom, such as a 5- to 6-membered non-aromatic heterocycle containing 1 to 2 heteroatoms, and among others, "5 ⁇ ⁇ 6-membered ring '' includes benzene, furan, thiophene, pyridine, cyclopentane, cyclohexane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, tetrahydro Benzyl is particularly preferred, with dropiran (preferably a 6-membered ring) being preferred.
- dropiran preferably a 6-membered ring
- the “5- to 6-membered ring” of the “substituted or 5- to 6-membered ring group” represented by R 1 has! /
- the “substituent” may be, for example, halogen , Nitro, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyl group, substituted V, thiol group (the sulfur atom is oxidized, May be substituted !, may be a sulfiel group or may be substituted to form a sulfol group), an optionally substituted amino group, An optionally substituted acyl, an esterified carboxyl group, a substituted !, or an aromatic group may be used.
- halogen as the substituent for R 1 include those described above, with fluorine and chlorine being particularly preferred.
- alkyl in the optionally substituted alkyl as the substituent of R 1 examples include a linear or branched alkyl having 1 to 10 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec —C-alkyl such as butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl
- Substituents in the group include halogen, nitro, sialylated hydroxyl groups, optionally substituted thiol groups (eg, thiol, C alkylthio, etc.), substituted !, and optionally amino groups (
- Razin piperidine, morpholine, thiomorpholine, pyrrole, 5- to 6-membered cyclic amino such as imidazole, etc., ester groups or carboxyl groups that may be amidated (eg, carboxyl, C alkoxycarbonyl, force Rubamoyl, mono C alkylcal
- alkoxy eg, methoxy, ethoxy, propoxy, butoxy, trifluoromethoxy, trifluoroethoxy
- optionally halogenated c alkoxy-C alkoxy eg,
- C alkylsulfol eg methanesulfol, ethanesulfol, etc.
- the number of substituents is preferably 1 to 3.
- the cycloalkyl in the cycloalkyl may be substituted as the substituent of R 1 , and examples thereof include C cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl and the like. It is done.
- Substituents in chloroalkyl include halogen, nitro, sialylated hydroxyl groups, substituted
- Vamino groups eg, amino-containing mono-C alkylamino, di-C alkylamino, tetrahydropi
- Ronole piperazine, piperidine, morpholine, thiomorpholine, pyroinole, 5- to 6-membered cyclic amino such as imidazole, etc.), esteroxy or an amidated carboxy group (eg, carboxyl, C alkoxy carb, force rumomoi, mono C
- V c alkoxy (eg, methoxy, ethoxy, propoxy, butoxy, trifluoromethoxy,
- Trifluoroethoxy optionally halogenated C alkoxy-C alcohol
- C alkyl sulphone eg methane sulphone, ethane sulphone
- substituent in the optionally substituted hydroxyl group as R 1 include (1) optionally substituted alkyl (eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl).
- C-alkyl such as tert-butynole, pentinole, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, preferably
- Saturated 5- to 6-membered heterocyclic groups containing 1 to 2 heteroatoms such as zolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrobiranyl, tetrahydrothiopyranyl, etc. (preferably tetrahydrobiral etc.); Etc.);
- alkaryl eg allyl, crotyl, 2-pentyl- Alkenyl having 2 to 10 carbon atoms, preferably lower (C) alkal
- cycloalkenyl for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Cycloalkenyl etc. for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Substituted ! may be aralkyl (eg, ferro-C alkyl (eg, benzil
- Formyl or substituted ! may! /, Isyl (eg, alkanoyl having 2 to 4 carbon atoms (eg, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfo having 1 to 4 carbon atoms- (Eg, methanesulfol, ethanesulfol, etc.));
- Isyl eg, alkanoyl having 2 to 4 carbon atoms (eg, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfo having 1 to 4 carbon atoms- (Eg, methanesulfol, ethanesulfol, etc.));
- Substituents such as optionally substituted aryl (for example, phenyl, naphthyl, etc.)
- the substituents are halogen, nitro, sheared hydroxyl group, and optionally substituted thiol group (eg, thiol, C
- Halogenated! / ⁇ C alkyl eg, trifluoromethyl, methyl
- c alkoxy eg, methoxy, ethoxy,
- Propoxy, butoxy, trifluoromethoxy, trifluoroethoxy and the like; preferably halogenated, may be C alkoxy), formyl, C alkanol (eg, acetyl)
- C alkyl sulphone eg methane sulphone, ethane sulphone
- a 5- to 6-membered aromatic heterocyclic ring eg, furan, thiophene, Ronole, imidazole, pyrazole, thiazole, oxazole, isothiazole, isoxazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, triazole, etc.Nitrogen atom, sulfur atom, and oxygen nuclear power 1 to 2 selected heteroatoms 1 to 2 5- to 6-membered aromatic heterocycle containing 4; etc .; the heterocycle has! /, May!
- substituents include halogen, nitro, silane-containing hydroxyl group, thiol group, amino group , Carboxyl group, halogenated, C alkyl (eg, trifluoromethyl, methyl, ethyl, etc.), halo
- Rogenated or c-alkoxy eg, methoxy, ethoxy, propoxy, butoxy
- C alkylsulfol eg, methanesulfol, ethanol
- Examples of the substituent in the optionally substituted thiol group as the substituent of R 1 include those similar to the above-mentioned “substituted as the substituent of, or may be a substituent in the hydroxyl group”. But among them
- alkyl for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, noel, decyl C alkyl, such as
- cycloalkyl for example, C cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.
- Substituted ! may be aralkyl (eg, ferro-C alkyl (eg, benzil
- aryls which may be substituted (eg phenyl, naphthyl etc.),
- Amino groups eg, mono-containing mono-C alkyl-containing di-C alkyl-containing tetrahydropyro
- Rifluoroethoxy which may be halogenated c alkoxy-C alcohol
- Xyoxy eg, methoxymethoxy, methoxyethoxy, ethoxyethoxy, trifluoromethoxyethoxy, trifluoroethoxyethoxy, etc.
- formyl eg, methoxymethoxy, methoxyethoxy, ethoxyethoxy, trifluoromethoxyethoxy, trifluoroethoxyethoxy, etc.
- C alkanol eg, acetyl
- C alkyl sulphone eg methane sulphone, ethane sulphone
- the substituent of the amino group may be the same substituent as the above-mentioned “substituent of the hydroxyl group”.
- Examples include 1 to 2 amino groups, etc.
- (1) alkyl which may be substituted for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s ec-butanol C-alkyl such as tert-butinole, pentinole, isopentinole, neopentinole, hexinole, heptyl, octyl, noel, decyl, preferably lower (C) alkyl which may be substituted (for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s ec-butanol C-alkyl such as tert-butinole, pentinole, isopentinole, neopentinole,
- cycloalkyl for example, C cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.
- Alkal which may be substituted (for example, allyl, crotyl, 2-pental, 3-hexyl, etc., C2-C10, preferably lower (C Arkuke
- cycloalkenyl for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Cycloalkenyl etc. may! /, Isyl (eg, alkanoyl having 2 to 4 carbon atoms (eg, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfo having 1 to 4 carbon atoms- (Eg, methanesulfol, ethanesulfol, etc.));
- An aryl which may be substituted (for example, phenyl, naphthyl, etc.) is preferable,
- optionally substituted acyl and (6) optionally substituted aryl may have as halogen, nitro, sialylated hydroxyl group, substituted Any thiol group (eg, thiol, C alkylthio, etc.)
- Camino groups eg, mono-containing mono-C alkyl-containing di-C alkyl-containing tetrahydropyro
- 1-4 1-4 diol piperazine, piperidine, morpholine, thiomorpholine, pyrrole, 5- to 6-membered cyclic amino such as imidazole), carboxyl group which may be esterified or amidylated (E.g., carboxyl, C alkoxy carb, force rumomoi, mono C alkyl
- Alkoxy eg, methoxy, ethoxy, propoxy, butoxy, trifluoromethoxy, trimethyl
- 1-4 1-4 eg, methoxymethoxy, methoxyethoxy, ethoxyethoxy, trifluoromethoxyethoxy, trifluoroethoxyethoxy, etc.
- formyl eg, methoxymethoxy, methoxyethoxy, ethoxyethoxy, trifluoromethoxyethoxy, trifluoroethoxyethoxy, etc.
- C alkanol eg, acetyl
- C alkylsulfur eg methanesulfur, ethanesulfonyl
- the amino group which may be substituted as the substituent of R 1 is bonded to the substituents of the amino group to form a cyclic amino group (for example, tetrahydropyrrole, piperazine, piperidine, morpholine, A 5- to 6-membered ring nitrogen atom such as thiomorpholine, pyrrole, imidazole, etc. formed by removing one hydrogen atom, and a cyclic amino group having a bond on the nitrogen atom, etc. .
- a cyclic amino group for example, tetrahydropyrrole, piperazine, piperidine, morpholine, A 5- to 6-membered ring nitrogen atom such as thiomorpholine, pyrrole, imidazole, etc. formed by removing one hydrogen atom, and a cyclic amino group having a bond on the nitrogen atom, etc.
- the cyclic amino group may have a substituent, and as such a substituent, halogen, nitro, sialylated hydroxyl group, an optionally substituted thiol group (eg, thiol, C alkylthio etc.), substituted ⁇ ⁇ ⁇ ⁇ amino group (ex. Mono C alkylamino, Di C alkylamino, Tetrahydropyrrole, Piperazine, Pi
- C alkylsulfol eg, methanesulfol, ethanesulfol, etc.
- the number of substituents is preferably 1 to 3.
- optionally substituted alkyl eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, noel, decyl C alkyl, such as
- An optionally substituted cycloalkyl for example, C cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.
- Alkyl which may be substituted for example, allyl, crotyl, 2-pental, 3-hexyl, etc., C2-C10, such as lower (C Arkuke
- cycloalkenyl for example, 2-cyclopental, 2-cyclohexal, 2-cyclopentalmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Cycloalkenyl etc. for example, 2-cyclopental, 2-cyclohexal, 2-cyclopentalmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- An optionally substituted 5- to 6-membered monocyclic aromatic group for example, phenyl, pyridyl, etc.
- a carbo ol group or a sulfonyl group eg, formi , Acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivalol, hexanol, heptanol, otatanyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, crotonyl,
- Good amino group eg, amino, mono-C alkylamino-containing di-C alkylamino-containing tetrahydro
- 1-4 1-4 Lucoxy eg, methoxymethoxy, methoxyethoxy, ethoxyethoxy, trifluoromethoxy ethoxy, trifluoroethoxyethoxy, etc.
- formyl eg, methoxymethoxy, methoxyethoxy, ethoxyethoxy, trifluoromethoxy ethoxy, trifluoroethoxyethoxy, etc.
- C alkanol eg, acetyl
- C alkylsulfol eg methanesulfur, ethanesulfur
- alkyl eg methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec butyl, tert butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, noel, decyl, etc.
- alkyl good
- An optionally substituted cycloalkyl for example, C cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.
- C cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.
- Alkyl which may be substituted (for example, allyl, crotyl, 2-pental, 3-hexyl, etc., C2-C10, preferably lower (C) alkenyl) -
- cycloalkenyl for example, 2-cyclopental, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc., C3-C7 cycloalkenyl, etc.
- Aralkyls which may be substituted (eg, phenyl, naphthyl, etc.) bonded to a carboxy group, preferably carboxyl, lower (C) alkoxycarbo
- aryloxycarbonyl eg, methoxycarbonyl, ethoxycarbonyl, propoxycarbol, phenoxycarbol, naphthoxycarbol, etc.
- Alkyl optionally substituted ( 3) optionally substituted cycloalkyl, (4) optionally substituted alkenyl, (5) optionally substituted cycloalkyl, and (6) substituted!
- the substituent may be halogen, nitro, sialylated hydroxyl group, optionally substituted thiol group (eg, thiol, C alkylthio, etc.), substituted !, etc.
- Camino group e.g.
- halogenated and may be alkoxy (eg, methoxy, eth
- Toxyl ethoxyethoxy, trifluoromethoxyethoxy, trifluoroethoxyethoxy, etc.
- formyl C alkanol (eg, acetyl, propiool, etc.), C alkyls
- the aromatic group in the aromatic group may be substituted as a substituent of R 1 .
- condensed heterocyclic aromatic groups such as indanol, benzothiophene, benzoxazole, benzthiazonole, indazonole, benzimidazole, quinoline, isoquinoline, quinoxaline, phthalazine, quinazoline, cinnoline, and imidazopyridine.
- substituents for these aromatic groups include halogen, nitro, silane-containing hydroxyl groups, optionally substituted thiol groups (eg, thiol, C alkylthio, etc.), substituted !, and optionally amino groups.
- Alkylsulfol eg, methanesulfol, ethanesulfol, etc.
- the number of substituents is preferably 1 to 3.
- substituents for R 1 may be the same or different and may be substituted at any position of the ring. Further, when the “5- to 6-membered ring” of the “optionally substituted 5- to 6-membered ring” represented by R 1 has two or more substituents, among these, the two substituents are mutually In combination with, for example, lower (C) alkylene (e.g. trimethylene, tetramethylene
- Anolechilentio eg, -O-CH—S, -O-CH-CH—S, etc.
- lower C
- Lower (C) alkylenediamine eg, —NH—CH—NH—, —NH—CH— CH
- thia lower (C) anolechilenamino e.g., -S-CH- NH-, -S-C
- the divalent group formed by combining two substituents of R 1 with each other is a “5- to 6-membered ring” of the “substituted and may be a 5- to 6-membered ring” represented by R 1 .
- a substituent similar to the “substituent” (a norogen atom, a nitro, an optionally substituted alkyl, an optionally substituted cycloalkyl, a substituted A hydroxyl group which may be substituted, a thiol group which may be substituted (the sulfur atom may be oxidized and substituted, may be substituted, or may be a sulfiel group or may be substituted to form a sulfol group. ), Substituted !, may! / Amino groups, optionally substituted acyls, esterified or amidated carboxyl groups, substituted, and May have 1 to 3 aromatic groups, etc.).
- the “5- to 6-membered ring” of the “substituted or 5- to 6-membered ring group” represented by R 1 has! /,
- the “substituent” may be, among others, halogen Or lower (C) alkoxylated
- lower (C 1) alkyl eg, methyl, ethyl, t-butyl, trifluoromethyl, methoxy
- Alkoxylated may be lower (C 1) alkoxy (eg, methoxy, ethoxy,
- Moyamino eg, amino, methinoreamino, dimethylamino-containing honoreminoreamino, acetinoleamino, etc.
- 5- to 6-membered cyclic amino group eg, 1 pyrrolidinyl, 1-piperadjur, 1-piveridyl, 4 morpholino
- 4 morpholino 4 thiomorpholino, 1 imidazolyl, 4-tetrahydroviral, etc.
- Examples of the “divalent group having 1 to 4 atoms constituting the straight chain portion” represented by X 1 and X 2 include one (CH 3) — [a ′ is an integer of 1 to 4 (preferably Is an integer between 1 and 2]
- imino groups e.g., lower (C) alkyl, lower (C) cycloalkyl,
- the other is coupled with the ring B may be a right or left bond, but if the X 1, when it binds to the ring A via the right binding Gote is preferred instrument X 2, Bonding to ring B via the left hand is preferred.
- X 1 is a bond, — (CH 2) —O— [b, is an integer of 0, 1 or 2 (preferably 0 to 1
- X 2 includes-(CH)-[a 'represents an integer of 1 to 2],-(CH)-X 3 — [b, 0 to
- X 3 represents an optionally substituted imino group, a carbonyl group, an oxygen atom or an optionally oxidized sulfur atom]
- —CH CH—, —CO—NH—, —SO -
- NH is preferred, and one CO—NH is more preferred! /.
- the divalent group represented by X 1 and X 2 may have a substituent at any position (preferably on a carbon atom). Anything that can be attached to the other chain is acceptable, for example, lower (C) alkyl (eg, methyl,
- Til propyl, isopropyl, butyl, isobutyl, sec butyl, tert butyl, pentyl, isopentyl, neopentyl, hexyl, etc.), lower (C) cycloalkyl
- cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl Etc.
- formyl lower (C) alkanoyl (eg, acetyl, propionyl, butyryl)
- phosphono group which may be esterified carboxyl group which may be esterified, hydroxyl group, oxo, etc., preferably lower alkyl having 1 to 6 carbon atoms (preferably C Alkyl), hydroxyl group, oxo and the like.
- the phosphono group which may be sterilized includes P (O) (OR 7 ) (OR 8 ) [wherein R 7 and R 8 are each hydrogen, an alkyl group having 1 to 6 carbon atoms, or 3 carbon atoms. A cycloalkyl group of ⁇ 7, and R 7 and R 8 may be bonded to each other to form a 5- to 7-membered ring.
- the alkyl group having 1 to 6 carbon atoms represented by R 7 and R 8 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec butyl, tert butyl, pentyl, isopentyl, neopentyl.
- a cycloalkyl having 3 to 7 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc., preferably a chain-like C 1-6 Lower alkyl, more preferably lower alkyl having 1 to 3 carbon atoms.
- R 7 and R 8 may be the same or different but are preferably the same.
- R 7 and R 8 are bonded to each other to form a 5- to 7-membered ring, R 7 and R 8 are bonded to each other, and — (CH 2)
- the side chain may have a substituent.
- a strong substituent include a hydroxyl group and a halogen.
- the esterified carboxyl group of the esterified carboxyl group is a carboxyl group and an alkyl group having 1 to 6 carbon atoms or a cycloalkyl group having 3 to 7 carbon atoms.
- oxyballs for example, methoxycarbon, ethoxycarbon, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec butoxycarbonyl, tert butoxycarbonyl, pentyloxycarbon, hexyl
- oxyballs for example, oxyballs.
- the “5- to 6-membered ring” of the “optionally substituted 5- to 6-membered ring” represented by A includes C cycloalkane (eg, cyclopentane, cyclohexane) Etc.), C cycloalkene
- C cycloalkadiene eg 2, 4-cyclopentagen, 2
- 5-6 membered saturated or unsaturated alicyclic hydrocarbons such as benzene, 4-cyclohexagen, 2,5-cyclohexagen, etc.); 6-membered aromatic hydrocarbons such as benzene; oxygen atom, sulfur atom, Nitrogen atom isotropic 5- to 6-membered good containing at least one (preferably 1 to 4, more preferably 1 to 2) selected heteroatoms (preferably 1 to 2). Aromatic heterocycles, saturated or unsaturated non-aromatic heterocycles (aliphatic heterocycles), and the like.
- aromatic heterocycle refers to a 5- to 6-membered aromatic monocyclic heterocycle (for example, furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, 1, 2, 3 —Oxadiazole, 1, 2, 4-Oxadiazole, 1, 3, 4-Oxadiazole, furazane, 1, 2, 3-thiadiazole, 1, 2, 4-thiadiazole, 1, 3, 4-thiadiazole, 1, 2, 3-triazole, 1, 2, 4-triazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, etc.).
- non-aromatic heterocycle examples include pyrrolidine, tetrahydrofuran, Thiolane, piperidine, tetrahydropyran, morpholine, thiomorpholine, piperazine, pyran, oxepin, chepin, azepine, etc. 6-membered saturated or unsaturated non-aromatic heterocycles (aliphatic heterocycles), etc., or 5- to 6-membered non-saturated partially or fully double bonds of the above-mentioned aromatic monocyclic heterocycle An aromatic heterocyclic ring is mentioned.
- 5- to 6-membered ring of the “substituted !, may! /, 5- to 6-membered ring” represented by A, a 5- to 6-membered aromatic ring is preferred, and benzene, furan, and thiophene are preferred. , Pyrrole, pyridine (preferably a 6-membered ring) and the like are preferable, and benzene is particularly preferable.
- the “5-6 membered ring” of “substituted !, mayo! /, 5-6 membered ring” represented by A has! /, May! / ⁇ “substituent” Examples thereof include those similar to the “substituent” which the “5- to 6-membered ring” of the “substituted or 5- to 6-membered ring group” represented by R 1 may have.
- the substituents of A may be substituted at any position of the ring, 1 to 4 (preferably 1 to 2), the same or different, and may be the positions represented by E and E or other positions. Replace any
- Examples thereof include C_alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl and the like.
- Examples of the lower alkoxy group of the “substituted or lower alkoxy group” represented by R 3 include C alkoxy such as methoxy, ethoxy, propoxy and butoxy.
- substituents that the “substituted or lower alkyl group” and “substituted or lower alkoxy group” may have include halogen (eg, fluorine, chlorine). Bromine, iodine), hydroxyl group, amino-containing mono (lower alkyl) amino-containing di (lower alkyl) ami-containing lower alkanol, and the like.
- Examples of the lower alkyl possessed by the mono (lower alkyl) amino and di (lower alkyl) amino are the same as the lower alkyl group of the “optionally substituted lower alkyl group” represented by R 3 above. Can be given.
- Examples of the lower alkanol include C alkanoyl such as acetyl, propiol, butyryl, isoptylyl and the like.
- halogen atom represented by R 3
- examples of the “halogen atom” represented by R 3 include fluorine, chlorine, bromine and iodine.
- R 3 may be substituted !, or a lower C alkyl group or a halogen atom may be substituted.
- the “8-10 membered ring” of the “optionally substituted 8-10 membered ring” represented by B is, for example, the formula:
- Y ′ represents a divalent group, and other symbols are as defined above), and may have a substituent at any substitutable position. Examples include member rings.
- the divalent group represented by Y ′ represents a divalent group that forms an 8- to 10-membered ring in which ring B may be substituted.
- the divalent linear hydrocarbon group of of However, the sum of the carbon number of Alk and Alk is 5 or more al a2
- the linear hydrocarbon group is shown. However, the sum of the carbon number of Alk and Alk is 4 or less e6 e7
- Y for example, -0- (CH)-, -0- (CH)-, -0- (CH)-, -0- (CH
- O)-(CH)-(111 represents an integer from 0 to 2),-(11-3 (0)-(CH) one (m is 0 m 2 5 2 m 2 2
- Ring B is preferably an 8-membered ring.
- the divalent group may have a substituent, and as the substituent, the “5- to 6-membered cyclic group” represented by R 1 may be “5- Even if the “six-membered ring” has a force similar to that of the “substituent” and oxo, etc., lower (C) alkyl (eg, methyl)
- substituents of the divalent group may be the same or different and may be substituted.
- the substitution position may be any as long as it can be bonded to the divalent group.
- the “8-10 membered ring” of “substituted !, may! /, 8-10 membered ring” represented by B has! /, May be V ⁇ “substituent” is R The same as the “substituent” that may be possessed by the “5- to 6-membered ring” of the “substituted !, may! /, 5- to 6-membered ring group” represented by 1 and oxo, etc. Can be mentioned.
- a group having a divalent group represented by the formula: In particular, in the main chain, the formula N (R °)-[wherein represents a hydrogen atom or a substituent.
- R includes a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxyl group, and an optionally substituted thiol group (the sulfur atom is oxidized).
- it may be amidated, may be a carboxyl group, substituted !, may! /,
- An acyl group or the like preferably a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted Heterocyclic groups, substituted, and even more preferred are acyl groups.
- a hydrogen atom an optionally substituted hydrocarbon group, a substituted
- the acyl group may be substituted and substituted !, or the hydrocarbon group may be halogenated or hydroxylated, and may be c alkyl, halogenated or hydroxylated.
- C alkyl is preferred and is substituted !, and as the acyl group,
- C alkanoyl which may be hydroxylated, is more preferred, especially propylene.
- R isobutyl, isobutenyl or 3-hydroxy-2-methylpropyl is preferred.
- R ° the formula — (CH 2) — R x (wherein, s represents 0 or 1,
- Substituted may be a 5- to 6-membered monocyclic aromatic group (for example, the same as the “5- to 6-membered monocyclic aromatic group” exemplified in the section of ring A).
- hydrocarbon group of the “substituted or hydrocarbon group”, for example,
- Alkyl for example, C alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butinole, tert-butinole, pentinole, isopentinole, neopentinole, hexinole, heptyl, octyl, noel, decyl, etc. Is lower (C) alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butinole, tert-butinole, pentinole, isopentinole, neopentinole, hexinole, heptyl, octyl, noel, decyl, etc. Is lower (C) alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-but
- Cycloalkyl for example, C cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.
- alkellels e.g. allyl, crotyl, 2-pentale, 3-hexyl, etc., alkales having 2 to 10 carbon atoms, preferably lower (C) alkale, etc.
- Cycloalkenyl for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc., cycloalkenyl having 3 to 7 carbon atoms
- Alkyls eg, ethur, 1-propiel, 2-probule, 1-butur, 2 pentyl, 3 hexyl, etc., alkyls having 2 to 10 carbon atoms, preferably lower (C) alkyl -And the like);
- Aralkyl eg, ferro-C alkyl (eg, benzyl, phenethyl, etc.)
- aryl eg, ferrule, naphthyl, etc.
- Cycloalkyl-alkyl (for example, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, etc.)
- cycloalkylalkyl may have include halogen, nitro, sialylated hydroxyl group, substituted thiol group (eg, thiol, C alkylthio etc.), substituted
- amino groups eg, amino, mono-C alkylamino di-C alkylamino,
- Tetrahydropyrrole, piperazine, piperidine, morpholine, thiomorpholine, pyrrole, 5- to 6-membered cyclic amino such as imidazole, etc. may be esterified or amidified ⁇ carboxyl groups (eg, carboxyl, C Alkoxy carbo, force rumomois,
- aromatic heterocycle examples include nitrogen such as furan, thiophene, pyrrole, imidazole, pyrazole, thiazole, oxazole, isothiazole, isoxazole, tetrazole, pyridine, pyrazine, pyrimidin, pyridazine, triazole, oxadiazole, thiadiazole and the like.
- Atoms, sulfur atoms, and oxygen nuclear power include 5- to 6-membered aromatic heterocycles containing 1 to 4 selected heteroatoms
- examples of the non-aromatic heterocycle include: Tetrahydrofuran, tetrahydrothiophene, dioxolane, dithiolane, oxathiolane, pyrrolidine, pyrroline, imidazolidine, imidazoline, virazolidine, pyrazoline, piperidine, piperazine, oxazine, oxadiazine, thiazine, thiadiazine, morpholine, thiomol 5- to 6-membered non-aromatic heterocyclic ring containing 1 to 2 heteroatoms selected from nitrogen, sulfur and oxygen such as holin, pyran and tetrahydropyran and the above aromatic Examples include non-aromatic heterocyclic rings in which some or all of the heterocyclic rings are saturated bonds (preferably aromatic heterocyclic rings such as pyrazole, thiazole
- substituted and optionally acyl group includes the “5- to 6-membered cyclic group” of the “substituted and optionally 5- to 6-membered cyclic group” represented by R 1 .
- substituent “substituted and optionally hydroxyl group”, “optionally substituted thiol group”, “optionally substituted amino group”, “esterified, And a carboxyl group ”, and the same as the“ substituted and optionally acyl group ”.
- the “substituted and optionally amino group” or the like is bonded to a carbo group, preferably rubamoyl, mono-C alkyl group.
- Y 3 as formyl as a substituent, substituted! May be ⁇ C alkyl, substituted
- a heterocyclic group, substituted ! may, allylmethyl, or a substituted, imino group optionally having a heterocyclic methyl is represented by Y (R °) — They mean those that fall into these definitions. Among these, 1) C alkyl, 2) C alkyl
- Methyl (above 1), 2) may be substituted with halogen or hydroxyl, and 3), 4), 5) and 6) may be substituted with halogen, halogen or hydroxyl! C alkyl
- substituent of B may be substituted at any position (including E and E) of 1 to 7 (preferably 1 to 2), the same or different, and the position of E Is unsubstituted
- E and E are each optionally substituted carbon atoms (preferably
- Examples include groups formed by removing two atoms, including benzene, furan, thiophene, pyridine, pyridazine, pyrimidine, benzimidazole, cyclopentane, cyclohexane, pyrrolidine, piperidine, piperazine, morpholine.
- Divalent cyclic groups formed by removing two hydrogen atoms such as thiomorpholine and tetrahydropyran
- a divalent cyclic group formed by removing two hydrogen atoms from benzene, pyridine, pyridazine, benzimidazole, cyclohexane, piperidine (preferably benzene) force is preferably used.
- the “divalent cyclic group” represented by Z 1 is the same as the “5- to 6-membered ring” of the “substituted or 5- to 6-membered ring group” represented by R 1 .
- it may have a substituent similar to the “substituent”, and in particular, as a substituent, a halogen atom (eg, fluorine, chlorine, bromine, etc.), substituted with a halogen atom! /, Or C alkyl group (eg, methyl, ethyl, trifluoromethyl, trifluoro) Substituted with a halogen atom, and a c alkoxy group (
- Examples include methoxy, ethoxy, propoxy, triflumizole Ruo b methoxy, although etc. triflumizole Ruo b ethoxy, etc.) which are preferred, it has been sigma preferred having no X 2 and z 2 other substituents are z 1
- the substitution position of Z 2 is preferably the para position of X 2 .
- Z 1 may be substituted with 1) a halogen atom, 2) substituted with a halogen atom, C alkyl group or 3) substituted with a halogen atom!
- the divalent group represented by Z 2 is, for example,
- Z 2a and Z 2b are each 0, S (0) m (m is 0, 1 or 2), an optionally substituted imino group (-N (R a )-) or a bond, and W 1 is a substituted, alkylene group, substituted, or an alkylene group, or a bond.
- the bonding position of Z 2 may be any position when Z 1 is, for example, a benzene ring, but is preferably the para position.
- the substituent () of the optionally substituted imino group represented by Z 2a and Z 2b includes a hydrogen atom, substituted or lower (C) alkyl [eg, methyl, ethyl, propyl,
- C-alkylated cyanogens eg, cyanoethyl, cyanopropyl
- Class (C) alkylsulfonyl (methylsulfonyl, ethylsulfonyl, etc.)
- Alkylene group of “substituted !, may! /, Alkylene group” represented by W 1 includes, for example, an alkylene chain represented by — (CH 2) ⁇ (kl is an integer of 1 to 4). Can be mentioned.
- W 1
- — (CH 2) — (CH ⁇ CH) — (CH 2) — (k2 and k3 may be the same or different. 0, 1 Or 2 However, the sum of k2 and k3 is 2 or less).
- the alkylene group and alkene group represented by W 1 may have a substituent at any position (preferably on a carbon atom). Any one can be used as long as it can be bonded to a chain or an alk-lene chain.
- lower (C 1) alkyl eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s
- ec-butinole ec-butinole, tert-butinole, pentinole, isopentyl, neopentyl, hexyl, etc.
- lower (C) cycloalkyl eg, cyclopropyl, cyclobutyl, cyclopentyl,
- phosphono group which may be esterified, carboxyl group which may be esterified or amidated, hydroxyl group, oxo, hydroxyimino group, lower optionally substituted group ( C) alkoxyimino group and the like, preferably
- Simino group hydroxyl group, cyano group, ester group or carboxy group which may be amidated (eg, carboxyl, C alkoxycarbonyl, strong rubamoyl, mono carbon
- the phosphono group which may be esterified includes P (O) (OR 9 ) (OR 10 ) [wherein R 9 and R 1G are each hydrogen, an alkyl group having 1 to 6 carbon atoms, or 3 carbon atoms. A cycloalkyl group of ⁇ 7, wherein R 9 and R 1G are bonded to each other to form a 5- to 7-membered ring.
- the alkyl group having 1 to 6 carbon atoms represented by R 9 and R 1C) is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl.
- Neopentyl, hexyl and the like, and the cycloalkyl having 3 to 7 carbon atoms includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- R 9 and R 1C) may be the same or different, but are preferably the same.
- R 9 and Are bonded to each other to form a 5- to 7-membered ring, R 9 and R 1C> are bonded to each other, and- (CH
- the side chain may have a substituent.
- a strong substituent include a hydroxyl group and a halogen.
- the esterified carboxyl group may be an ester of a carboxyl group and an alkyl group having 1 to 6 carbon atoms or a cycloalkyl group having 3 to 7 carbon atoms, such as methoxycarbohydrate.
- the amide form of the carboxyl group may be a carboxyl group and an alkylamino group having 1 to 6 carbon atoms, a cycloalkylamino group having 3 to 7 carbon atoms, or a 5- to 8-membered cyclic amine (example: , Pyrrolidine, piperidine, morpholine, etc.), for example, rubamoyl, mono C alkyl rubamoyl, di C alkyl rubamoyl, cyclo
- Examples thereof include pentylaminocarbonyl, cyclohexylaminocarbonyl, pyrrolidinocarbonyl, piperidinocarbol, morpholinocarbon, thiomorpholinocarbole and the like.
- Z 2 either Z 2a or Z 2b is 0, S (0) m (m is 0, 1 or 2) or — N (R a )-(R a is a hydrogen atom or substituted ⁇ It may be a lower C alkyl group.
- W is — (CH 2) ⁇ (p is an integer from 1 to 3) or Z 2 is
- a divalent group that is -CH (OH)- is preferred.
- Z 2 is one CH (OH) — or a divalent group is more preferred.Z 2 is one CH—, — CH (OH) —, — S (O) — CH— (m Is preferably 0, 1 or 2.
- z 2a represents a bond, s, so or so, but in this case so is preferred so The configuration of (S) is preferred.
- the nitrogen atom is quaternary ammonium - are ⁇ beam on or Okishidi spoon, even I, Amino group "include, Examples include 1- to 2-substituent groups, amino groups having 3 substituents, and nitrogen-atom grade ammonia. If there are two or more substituents on the nitrogen atom, the substituents may be the same or different. If there are three substituents on the nitrogen atom, N + R P R P R — N + R P R P R q and N + R P R q Rr ( , R q and R 1 are different from each other, showing a hydrogen or a substituent) may be any type of Amino groups.
- the counter amino acid of the amino group includes anions of halogen atoms (eg, Cl_, Br ", I-, etc.) , Hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and other anions that also induce inorganic acidity, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, succinic acid, succinic acid, apple Acids, methanesulfonic acid, benzenesulfonic acid, p Toluenesulfonic acid and other organic acid forces induced anions, acidic amino acid forces such as aspartic acid and glutamic acid induced anions, Cl_, Br 1, I, etc. are preferred.
- halogen atoms eg, Cl_, Br ", I-, etc.
- alkyl eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec butyl, tert butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, noel, decyl, etc.
- alkyl good
- cycloalkyl eg, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyanooctyl, etc.
- the cycloalkyl contains one heteroatom selected from a sulfur atom, an oxygen atom, and a nitrogen atom, and includes oxolan, thiolane, aziridine, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, tetrahydropyran, tetrahydrothione.
- Pyran, tetrahydrothiobirane 1-oxide, piperidine, etc. (preferably 6-membered tetrahydropyran, tetrahydrothiopyran, piperidine, etc.) may be bonded to the amino group which is 3rd position Or 4th (preferably 4th) is preferred;
- the cycloalkyl is condensed with a benzene ring to form indane (eg, indan-1-yl, indan-1-yl, etc.), tetrahydronaphthalene (eg, tetrahydronaphthalene-5-yl).
- indane eg, indan-1-yl, indan-1-yl, etc.
- tetrahydronaphthalene eg, tetrahydronaphthalene-5-yl
- tetrahydronaphthalene-6-yl preferably indane etc.
- the cycloalkyl is bridged via a linear atomic chain having 1 to 2 carbon atoms, and bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, Bicyclo [3.2.1] octyl, bicyclo [3.2.2] nor, etc. (preferably, cyclohexyl having a bridge through a straight chain of 1 to 2 carbon atoms, etc. More preferably, it may form a bridged cyclic hydrocarbon residue such as bicyclo [2.2.1] heptyl);
- Alkal which may be substituted (for example, allyl, crotyl, 2-pental, 3-hexyl, etc., C2-C10, preferably lower (C Arkuke
- cycloalkenyl for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Cycloalkenyl etc. for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Substituted ! may be aralkyl (eg, ferro-C alkyl (eg, benzil
- Formyl or substituted ! may! /, Isyl (for example, alkanol having 2 to 4 carbon atoms (eg, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfo having 1 to 4 carbon atoms- (Eg, methanesulfol, ethanesulfol, etc.), C1-C4 alkoxycarbonyl (eg, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), C7-C10 aralkyl Oxycarbonyl (eg, benzyloxycarbonyl, etc.);
- Isyl for example, alkanol having 2 to 4 carbon atoms (eg, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfo having 1 to 4 carbon atoms- (Eg, methanesulfol
- optionally substituted aryl eg, naphthyl, etc.
- An optionally substituted heterocyclic group e.g., furan, thiophene, pyrrole, imidazole, pyrazole, thiazole, oxazole, isothiazole, isoxazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, triazole, oxadiazole
- Nitrogen atoms such as thiadiazole, sulfur atoms and oxygen nuclear power 5 to 6 membered aromatic heterocycles containing 1 to 4 selected heteroatoms or benzofurans, benzofurans, Indian monoles, benzothiophenes, Fused heteroaromatic groups such as nudoxazone, benzthiazonole, indazozone, benzimidazole, quinoline, isoquinoline, quinoxaline, phthalazine, quinazoline, cinnoline, imidazopyridine are also formed by removing one hydrogen atom.
- (1) optionally substituted alkyl, (2) optionally substituted cycloalkyl, (3) optionally substituted alkyl, (4) optionally substituted cycloalkenyl , (5) optionally substituted aralkyl, (6) optionally substituted acyl, (7) substituted, ally, and (8) substituted !, may, complex
- the ring group may have V, and the substituent may be halogen, halogenated, or lower (C) alkyl.
- a polar group such as a hydroxyl group, hydroxyl group, cyano group, ester group or carboxyl group (eg, hydroxy C alkyl)
- C alkylsulfur eg methanesulfur, ethanesulfonyl
- amino groups eg, amino, mono-C alkylamino di-C alkylamino,
- Tetrahydropyrrole, piperazine, piperidine, morpholine, thiomorpholine, pyrrole, 5- to 6-membered cyclic amino such as imidazole, etc. may be esterified or amidified ⁇ carboxyl groups (eg, carboxyl, C Alkoxy carbo, force rumomois,
- the “amino group which may be substituted and the nitrogen atom may be quaternary ammomized or oxidized” represented by R 2 is preferably
- Force may contain one selected heteroatom or may be condensed with a benzene ring Bridged via a straight chain of 1 to 2 carbon atoms, C cyclo Alkyl (e.g.
- Halogen, halogenated, lower (C) alkyl or halogenated It may have 1 to 3 lower (C) alkoxy! /, May! /, One lower (C)
- Halogen, halogenated may be lower (C 1) alkyl or halogenated
- Halogen, halogenated may be lower (C 1) alkyl, halogenated
- V may be lower (C) alkoxy, halogenated, may be lower (C) alkoxy
- a nitrogen atom which may contain a sulfur atom or an oxygen atom as a ring-constituting atom, which is represented by R 2 is quaternary ammomized or
- the ⁇ nitrogen-containing heterocycle '' of ⁇ optionally oxidized nitrogen-containing heterocyclic group '' includes pyrrole, imidazole, pyrazole, thiazole, oxazole, isothiazole, isoxazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine , Triazole, oxadiazole, thiadiazole, etc.
- heptane Azabicyclo [2.2.2] otatan (quinuclidine), etc. (preferably, bridging via a linear chain of 1 to 2 carbon atoms) Forming a bridged cyclic nitrogen-containing heterocycle of piperidine and the like.
- nitrogen-containing heterocycle pyridine, pyridazine, pyrazole, imidazole, triazole, tetrazole, imidazopyridine, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and azabicyclo [2.2.2.
- Octane preferably pyridine, imidazole, triazole, imidazopyridine, pyrrolidine, piperidine, morpholine
- the nitrogen atom of the “nitrogen-containing heterocycle” may be quaternary ammonia or oxidized.
- the counter of the “nitrogen-containing heterocyclic group that is converted into a nitrogen-containing nuclear-grade ammonia is used as a halogen atom.
- anions derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid ,
- Anion derived from organic acids such as trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, succinic acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid Among them, Cl_, Br ", I-, etc.
- the forces such as anions derived from acidic amino acids such as glutamic acid.
- The" nitrogen-containing heterocyclic group is a carbon atom or a nitrogen atom.
- the “nitrogen-containing heterocycle” may have, as a substituent, halogen, substituted, or lower (C) alkyl, substituted !, or lower (C). Alkoxy, substituted
- Good amino group eg, amino, mono-C alkylamino-containing di-C alkylamino-containing tetrahydro
- Carbon, formyl, lower (C 1) alkanoyl, lower (C 1) alkyl sulfole An optionally substituted heterocyclic group (e.g., furan, thiophene, pyrrole, imidazole, pyrazole, thiazole, oxazole, isothiazole, isoxazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, triazole, oxadiazole, thiadiazole, etc.
- heterocyclic group e.g., furan, thiophene, pyrrole, imidazole, pyrazole, thiazole, oxazole, isothiazole, isoxazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, triazole, oxadiazole, thiadiazole, etc.
- the “nitrogen-containing heterocyclic ring” The nitrogen atom of "may be oxidized.
- the “nitrogen-containing heterocycle” may have a “substituted and optionally lower (C 1) alkyl”, “optionally substituted lower (C 2) alkoxy” as a substituent, "Replaced
- each “cyclic group” may have include, for example, a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), halogenated, and lower (C 1) alkyl. ,
- a polar group such as a hydroxyl group, a cyano group, an ester group or an amidyl group
- a lower (C) alkyl group eg, hydroxy C alkyl group
- C alkylsulfol eg methanesulfur, ethanesulfur
- “which may be substituted may contain a sulfur atom or an oxygen atom, and may be nitrogen-atom class ammomized or oxidized”.
- the “nitrogen-containing heterocyclic ring” of the “nitrogen-containing heterocyclic group” may have a substituent as (1) halogen, (2) cyano, (3) hydroxyl group, (4) carboxyl group, (5) force rubermoyl group, (6) lower (C) alkoxy carbole, (7) lower (C) alkyl force rubermoyl or 5-6
- cyclic amino such as piperidine-containing morpholino carboyl, (8) halogen, hydroxyl group, cyano group, lower (C) alkoxy, esterified or amidated, may be carboxyl
- Substituted with a group may be lower (C) alkyl, (9) halogen, hydroxyl or lower (
- R 5 and R 6 may each be an optionally substituted hydrocarbon group.
- An optionally substituted hydroxyl group or an optionally substituted amino group preferably, an optionally substituted hydrocarbon group or an optionally substituted amino group; more preferably A substituted or unsubstituted hydrocarbon group
- R 5 and R 6 may be bonded to each other to form a cyclic group together with the adjacent phosphorus atom.
- alkyl eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec butyl, tert butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, noel, decyl, etc.
- alkyl good
- cycloalkyl for example, C cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.
- Alkal which may be substituted (for example, aryl having 2 to 10 carbon atoms such as allyl, crotyl, 2-pentale, 3-hexale, preferably lower (C) Arque
- Cycloalkenyl optionally substituted (for example, cycloalkenyl having 3 to 7 carbon atoms, such as 2 cyclopental, 2 cyclohexal, 2 cyclopentalmethyl, 2 cyclohexylmethyl, etc.) Can be mentioned); (5) Alkyl which may be substituted (eg, etul, 1 probe, 2 propyl, 1-butur, 2 pentyl, 3 hexyl, etc., preferably an alkyl having 2 to 10 carbon atoms, preferably Lower (C) alkyl etc.);
- aralkyl eg, phenyl C alkyl (eg, benzil
- aryls which may be substituted for example, phenyl, naphthyl and the like), and the like
- Substituted ! may be possessed by aryl, and the substituent may be halogen, nitro, sialylated hydroxyl group, or optionally substituted thiol group ( Eg, thiol, C alkylthio, etc.), substituted !, may be an amino group (eg, amino-containing mono-C
- optionally substituted hydroxyl group represented by R 5 and R 6 include, for example, (1) optionally substituted alkyl (eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec butyl, tert C alkyl such as butynole, pentinole, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, preferably low
- optionally substituted alkyl eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec butyl, tert C alkyl such as butynole, pentinole, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, preferably low
- cycloalkyl for example, cyclopropyl, cyclobutyl, C cycloalkyl such as clopentyl, cyclohexyl, cycloheptyl, etc.
- Alkal which may be substituted (for example, allyl, crotyl, 2-pental, 3-hexyl, etc., C2-C10, preferably lower (C Arkuke
- cycloalkenyl for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Cycloalkenyl etc. for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Substituted ! may be aralkyl (eg, ferro-C alkyl (eg, benzil
- Formyl or substituted ! may! /, Isyl (eg, alkanoyl having 2 to 4 carbon atoms (eg, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfo having 1 to 4 carbon atoms- (Eg, methanesulfol, ethanesulfol, etc.));
- Isyl eg, alkanoyl having 2 to 4 carbon atoms (eg, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfo having 1 to 4 carbon atoms- (Eg, methanesulfol, ethanesulfol, etc.));
- An aryl group that may be substituted (eg, phenyl, naphthyl, etc.) may be included, and a hydroxyl group may be mentioned.
- Alkyl which may be substituted (2) Cycloalkyl which may be substituted, (3) Alkyl which may be substituted, (4) Cycloalkenyl which may be substituted , (5) optionally substituted aralkyl, (6) optionally substituted acyl, and (7) substituted, may have an ariel! /, May! / Substituents include halogen, nitro, sheared hydroxyl groups, and optionally substituted thiol groups (eg, thiol, C
- Halogenated! / ⁇ C alkyl eg, trifluoromethyl, methyl
- c alkoxy eg, methoxy, ethoxy,
- Trifluoromethoxy, trifluoroethoxy, etc. Trifluoromethoxy, trifluoroethoxy, etc.), formyl, C alkanol (eg, Chill, propiool, etc.), C alkylsulfur (eg methanesulfur, ethane)
- R 5 and R 6 may be bonded to each other to form a cyclic group (preferably a 5- to 7-membered ring) with an adjacent phosphorus atom.
- a cyclic group may have a substituent.
- the substituent include halogen, nitro, sialylated hydroxyl group, an optionally substituted thiol group (eg, thiol, C alkylthio, etc.), !, But, the amino group (
- Razin piperidine, morpholine, thiomorpholine, pyrrole, 5- to 6-membered cyclic amino such as imidazole, etc., ester groups or carboxyl groups that may be amidated (eg, carboxyl, C alkoxycarbonyl, force Rubamoyl, mono C alkylcal
- alkyl eg, trifluoromethyl, methyl, ethyl, etc.
- optionally halogenated C alkoxy eg, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, etc.
- the counter ion may be an anion of a halogen atom (eg, Cl_, Br ", I-, etc.) , Hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc.
- a halogen atom eg, Cl_, Br ", I-, etc.
- Induced anions formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, succinic acid, succinic acid,
- organic acids such as malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and anions derived from acidic amino acids such as aspartic acid and glutamic acid.
- Cl _, Br ", such as ⁇ is preferable.
- alkyl for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, noel, decyl C alkyl, such as
- cycloalkyl Preferably lower (C) alkyl, etc.); (2) optionally substituted cycloalkyl (for example, C cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.)
- Alkal which may be substituted (for example, allyl, crotyl, 2-pental, 3-hexyl, etc., C2-C10, preferably lower (C Arkuke
- cycloalkenyl for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Cycloalkenyl etc. for example, 2-cyclopentyl, 2-cyclohexyl, 2-cyclopentylmethyl, 2-cyclohexylmethyl, etc. having 3 to 7 carbon atoms
- Isyl eg, alkanoyl having 2 to 4 carbon atoms (eg, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfo having 1 to 4 carbon atoms- (Eg, methanesulfol, ethanesulfol, etc.));
- One or two optionally substituted aryls may be used, and an amino group and the like may be mentioned.
- Alkyl which may be substituted (2) Cycloalkyl which may be substituted, (3) Alkyl which may be substituted, (4) Cycloalkenyl which may be substituted (5) optionally substituted acyl, and (6) optionally substituted aryl may have a halogen, nitro, sialylated hydroxyl group, optionally substituted, Thiol groups (eg, thiol, C alkylthio, etc.) are substituted! /
- Mino groups eg, mono-containing mono-C alkyl-containing di-C alkyl-containing tetrahydropyro
- 1-4 1-4 diol piperazine, piperidine, morpholine, thiomorpholine, pyrrole, 5- to 6-membered cyclic amino such as imidazole), carboxyl group which may be esterified or amidylated (E.g., carboxyl, C alkoxy carb, force rumomoi, mono C alkyl
- Alkyl eg, trifluoromethyl, methyl, ethyl, etc.
- Alkyl may be halogenated
- V c alkoxy (eg, methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy
- R 2 includes (1) an amino group in which the nitrogen atom which may be substituted may be quaternary ammonium or oxidated, and (2) a ring structure which may be substituted. It may contain a sulfur atom or oxygen atom as an atom! /, Which may be nitrogen-atom class ammomized or oxidized, or a nitrogen-containing heterocyclic group, (3) substituted It is preferable that it is an amidino group or (4) an optionally substituted gua-dino group. As R 2 , a nitrogen nuclear grade ammomation which may be substituted may be used.
- An amino group which may be substituted, a nitrogen atom which may contain a sulfur atom or an oxygen atom as a ring-constituting ring atom may be oxidized, a nitrogen-containing heterocyclic group, etc. Is more preferably substituted, a teamino group, and a sulfur atom as an optionally substituted ring member. Contain an atom or an oxygen atom! /, I also, such as the particularly preferred nitrogen-containing heterocyclic group,.
- R 2 is a group represented by the formula NRR "or ⁇ + RR'R" (wherein R, R 'and R “are each substituted! ⁇ aliphatic hydrocarbon group (aliphatic A chain hydrocarbon group and an aliphatic cyclic hydrocarbon group) or a substituted or unsubstituted alicyclic (non-aromatic) heterocyclic group) or a substituted nitrogen atom.
- NRR or ⁇ + RR'R
- the “optionally substituted aliphatic hydrocarbon group” and the “optionally substituted alicyclic heterocyclic group” represented by R, R ′ and R ” are the substituent R
- the “substituted or optionally amino group” shown in FIG. 2 may have! /, Or may be exemplified by the “substituted and optionally substituted aliphatic hydrocarbon group (for example, Each optionally substituted alkyl, cycloalkyl, alkyl, cycloalkenyl, etc.) ”and“ optionally substituted alicyclic bicyclic group (eg, optionally substituted 5 to 6 members) And non-aromatic heterocycles in the same manner.
- an optionally substituted chain hydrocarbon group (for example, each An optionally substituted alkyl, alkell, etc.) may be preferably substituted.
- R ′′ represents an optionally substituted alicyclic hydrocarbon group (preferably an optionally substituted C cycloalkyl group; more preferably a substituted !, may! /, Cyclohexyl )
- a substituted alicyclic heterocyclic group preferably a substituted saturated alicyclic heterocyclic group (preferably a 6-membered ring group); more preferably a substituted
- tetrahydrobiral, substituted may be tetrahydrothiobilal or substituted V, may be piperidyl; particularly preferably substituted, may be tetrahydrovillar Is preferred.
- the “nitrogen-containing aromatic heterocyclic group” of the “nitrogen-containing aromatic heterocyclic group in which the nitrogen atom which may be substituted may be oxidized” represented by R 2 is preferably exemplified by Among gin, imidazole, triazole, and imidazopyridine, imidazole and triazole are particularly preferable.
- Substituted ! may, hydrocarbon group”, “substituted, may, C alkyl” in the substituent represented by R 4 of the imino group of Y and the substituent of the imino group of Y, etc.
- the surface modifier used in the present invention covers the surface of the active ingredient, acid or base, and prevents adhesion of particles, thereby improving the active ingredient stability, disintegration rate, dissolution rate, and tabletability.
- examples thereof include anhydrous carboxylic acid (eg, AEROSIL, distributor: Nippon Aerosil), calcium silicate, aluminum silicate, titanium oxide, aluminum oxide, and the like.
- the free form and extremely poorly soluble compound includes amphoteric, basic, or acidic compounds.
- the powerful compound is an amphoteric or basic compound
- the object of the present invention is achieved. In order to do this, an acid is added, whereas if the powerful compound is an amphoteric or acidic compound, a base is added.
- amphoteric compound means a partial structure showing a pKa of 7.5 or more (preferably 8.5 or more) and a partial structure showing a pKa of 6.5 or less (preferably 5.5 or less) The compound which has this.
- basic compound refers to a compound having a partial structure showing a pKa of 7.5 or more (preferably 8.5 or more).
- acidic compound refers to a compound having a partial structure showing a pKa of 6.5 or less (preferably 5.5 or less).
- the acid used in the present invention is one that is solid at room temperature (15 to 25 ° C.) or one that is liquid. However, it is preferable to use an acidic compound that is a solid.
- the “acid” include carboxylic acids (eg, acetic acid, lactic acid, fumaric acid, tartaric acid, succinic acid, succinic acid (including succinic anhydride), oxalic acid, malonic acid, maleic acid, dl-malic acid.
- Stearic acid, adipic acid Stearic acid, adipic acid
- sulfonic acid eg, aminoethylsulfonic acid
- acidic polysaccharide eg, alginic acid
- acidic amino acid eg, glutamic acid, aspartic acid
- amino acid eg, glycine hydrochloride, hydrochloric acid
- mineral acid e.g, mineral acid, and the like, and these may be hydrates or anhydrides. These may be used alone or in combination of two or more.
- fumaric acid, adipic acid, malic acid, acetic acid, tartaric acid, succinic acid, and succinic acid are preferred because carboxylic acid is preferred.
- tartaric acid, fumaric acid or citrate which is a solid carboxylic acid at normal temperature, is preferred, and in particular, citrate is preferred.
- the base used in the present invention may be either a solid at room temperature (15 to 25 ° C.) or a liquid, but a basic compound that is a solid may be used.
- a basic compound that is a solid may be used.
- the “base” include hydroxide compounds (eg, potassium hydroxide, calcium hydroxide, sodium hydroxide, magnesium hydroxide), carbonate compounds (eg, sodium carbonate, sodium bicarbonate). , Potassium carbonate, potassium hydrogen carbonate), amine compounds which show alkalinity in aqueous solution, amido compounds, ketone compounds, etc., which may be hydrates or anhydrides. You may use one or more of these.
- the solid preparation of the present invention comprises, in addition to the above-mentioned ingredients, other medicinal ingredients other than those that are easily gelled, and excipients, disintegrants, binders, lubricants, and colorants used in the solid preparation. , A fragrance, and a light-shielding agent may be included.
- the “medicinal component” is not particularly limited.
- the medicinal component that is easily gelled is a compound of the formula (I)
- a reverse transcriptase inhibitor and a Z or protease inhibitor are used. They can be used in combination.
- specific examples of these drugs include zidovudine, didanosine, zanorecitabine, lamivudine, stavudine, saquinavir, ritonavir, indinavir, nelfinavir and the like.
- excipients include lactose, starch, sucrose, mannitol, crystalline cellulose, light anhydrous carboxylic acid, magnesium carbonate, calcium carbonate, calcium phosphate, sulfate Examples include russia, aluminum silicate, and aluminum metasilicate.
- disintegrant include carboxymethyl cellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, starch, low-substituted hydroxypropyl cellulose, and cross-linked insoluble polybulur pyrrolidone.
- binder examples include hydroxypropylcellulose, pregelatinized starch, sucrose, gelatin, gum arabic powder, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, crystals
- examples include cellulose, dextrin and pullulan.
- lubricant examples include stearic acid, calcium stearate, magnesium stearate, talc, colloidal silica and the like.
- coloring agent examples include yellow iron sesquioxide, iron ferric acid trioxide, and the like.
- the “perfume” may be either a synthetic product or a natural product, such as lemon flavor, lime flavor, orange flavor, strawberry flavor, and menthol.
- Examples of the “light-shielding agent” include titanium dioxide, talc, calcium carbonate, and magnesium carbonate.
- a preferred embodiment of the solid preparation of the present invention includes those containing talc or koji and magnesium stearate in addition to the above components.
- Examples of the dosage form of the solid preparation of the present invention include a round tablet or an oval tablet, and a tablet such as a coated tablet thereof. Of these, a coating agent is preferred.
- the content of the medicinal component easily gelled in the solid preparation of the present invention is not particularly limited, but is usually 0.1 to 45% (WZW) based on the whole solid preparation.
- the solid preparation of the present invention is preferably 0.1 to 20 parts by weight, more preferably 1 to: LO parts by weight, particularly preferably 1 to 5 parts by weight, based on 1 part by weight of a medicinal component that easily gels. Contains.
- the solid preparation of the present invention is preferably 0.05 to 20 parts by weight, more preferably 0.1 to 15 parts by weight, and particularly preferably 1 to 15 parts by weight of the surface modifier with respect to 1 part by weight of the medicinal component that is easily gelled. 0.5 to 5 parts by weight
- the content of acid or base in the whole solid preparation of the present invention is preferably 2 to 85% (w / w), more preferably 5 to 65% (w / w ), Particularly preferably 8 to 17% (w / w).
- the solid preparation of the present invention can be produced by combining known methods employed according to the dosage form. What is necessary is just to determine the conditions of each process according to a conventional method. However, at this time, before mixing the medicinal component easily gelled with the acid or base, it is important to mix the medicinal component easily gelled and / or the acid or base with the surface modifier in advance. . In addition, it is preferable to mix an acid (or base) with a surface modifier in advance, and in particular, it is preferable to mix both a medicinal ingredient that is easily gelled and an acid or base with the surface modifier. ⁇ .
- the solid preparation produced in this way is easily gelled, and is expected to have a structure in which a surface modifier is attached to the surface of a medicinal component and a small mass of Z or acid (or base). Therefore, it is expected that the excellent effect is exhibited.
- the present invention is not limited to this.
- a medicinal component that is easily gelled (hereinafter sometimes abbreviated as medicinal component) and a surface modifier are mixed to modify the surface of the medicinal component.
- a device having a stirring mechanism such as a mixer such as a tumbler mixer or a kneading granulator is used for the mixing.
- acid (or base) and a surface modifier are mixed to modify the surface of the acid (or base).
- these and a binder are mixed and granulated to prepare granules. Mixing and granulation are performed using a conventional granulator.
- an excipient and Z or a disintegrating agent, a medicinal component and / or a mixture obtained by previously mixing an acidic compound (pre-mix) and a binder may be mixed and granulated.
- the mixing and granulation of the medicinal component and Z or acid (or base) and the binder is preferably performed at about 0 to 100 ° C.
- the content of the binder used in the granules is about 0.1 to 50% by weight.
- the content of the excipient and disintegrant used in the granules is about 1 to 99.9% by weight and about 0.1 to 50% by weight, respectively.
- the resulting granule should contain 50% or more particles of 50 111 or 1.5 mm (preferably Contains more than 50% particles of 150 m to 1. Omm).
- the resulting granules may be dried at about 10-80 ° C for about 0.01-72 hours. Further, the prepared granules may be sized. For sizing, a commercially available sizing machine such as a power mill is usually used. The granulated granules contain 50% or more of particles of about 50 m to 1.5 mm (preferably 50% or more of particles of 150 m to 1. Omm). You can also add disintegrants such as croscarmellose sodium and lubricants such as magnesium stearate. Further, an acid (or base) subjected to surface modification may be added. The acid (or base) may be used as it is without surface modification.
- a commercially available mixer such as a tumbler mixer is usually used.
- the amount of disintegrant used and the content of lubricant are about 0.1 to 50% by weight and about 0.1 to 10% by weight, respectively, slightly more than the amount used in normal formulations.
- the obtained mixed granule may be used as it is as a granule, but is usually tailored into a dosage form such as a pill, a tablet, or a capsule. Preferably, it is formed into a tablet such as a round tablet, Honore or Oblong tablet.
- a commercially available molding machine such as a tablet machine is used for molding.
- the tableting pressure for molding into tablets is usually about 1 to 25 kN.
- Round tablets are usually about 5 to 20 mm in diameter and about 1 to 10 mm in thickness.
- Opal tablets usually have a major axis of about 7 to 20 mm, a minor axis of about 5 to 15 mm, and a thickness of about 1 to 10 mm.
- Oblong tablets usually have a major axis of about 7 to 20 mm, a minor axis of about 5 to 15 mm, and a thickness of about 1 to 10 mm.
- film coating may be further applied.
- a pan coating apparatus is usually used.
- film-coated tablets include film-coated round tablets, film-coated opal-type tablets, and film-coated oblong-type tablets.
- Film-coating liquids are high in film coatings such as hydroxypropyl methylcellulose. It can be prepared by dissolving or suspending the molecule in a solvent such as water.
- a colorant or a light-shielding agent is further added to the film coating solution.
- the product (tablet) temperature when sprayed with the film coating solution is preferably controlled to about 10 to 100 ° C. Control to about 30 to 80 ° C, more preferable to control to about 40 to 60 ° C Force S is more preferred.
- the solid preparation of the present invention can be produced, for example, by a production method including (Step A) and Z or (Step A ′) and (Step B) in the following steps.
- Step A Easily gelled if desired! Mixing the glaze active ingredient and surface modifier;
- Step B After step A (and Z or step A'), acid (or base) and surface Mixing a mixture containing a modifier with an easily gelled glaze active ingredient (or a mixture containing an easily gelled glaze active ingredient and a surface modifier).
- the medicinal component and the acid (or base) which are easily gelled are uniformly mixed.
- the medicinal component and the acid (or base) that are easily gelled are preferably powders, particularly 70% by weight or more (for example, 70% to 90% by weight, 80% by weight or more).
- a powder that passes through a 75 ⁇ m mesh is preferred.
- the average particle size of a strong powder is usually about 1 ⁇ m or more.
- the acid (or base) is a liquid, it can be absorbed by a carrier with the same particle size (eg, anhydrous carboxylic acid (eg, AEROSIL, distributor: Nippon Aerosil), calcium silicate, aluminum silicate). Can be used.
- the surface modifier preferably has a particle size of 1Z5 or less, more preferably 1Z10 or less, relative to the particle size of the medicinal component powder or acid (or base) powder that is easily gelled. More preferably, it is 1Z100 or less. . Specifically, the average particle size is about 5 ⁇ ! It is preferable that the thickness is about 5 ⁇ m, more preferably about 7 nm to 100 nm, and particularly preferably about 10 nm to 50 nm.
- the average particle diameter refers to the number-based median diameter.
- the solid preparation of the present invention is a tablet
- a mixture containing a medicinal ingredient, a surface modifier, and an acid (or base) that are easily gelled is tableted by a conventional method.
- a tablet is obtained.
- a coating agent can be obtained by coating this tablet by a conventional method.
- the above-described medicinal components that easily gel, the surface modifier, and the components other than the acid (or base) may be added in an appropriate step similar to the method for producing a normal solid preparation.
- the solid preparation of the present invention can be administered to a subject according to a usual administration method.
- the compound A has an average particle size of 1.52 ⁇ m
- the light anhydrous anhydrous has an average particle size of about 12 nm
- the anhydrous citric acid has 200 mesh (opening 75 ⁇ m). ) was passed through 92.7%.
- HPC-L hydroxypropylcellulose
- Compound A (56.9g), anhydrous citrate (150g), and light anhydrous caustic anhydride (air mouth gill) (24g) are thoroughly mixed in a bag and mixed together. Perform reforming. After that, in a fluidized bed granulator / dryer, the main ingredient 'acid-surface modifier mixture (230.9g), mantol (683.1g) and crystalline cellulose (160g) were mixed uniformly, and then hydroxypropylated in the machine. An aqueous solution in which cellulose (HPC-L) (24 g) was dissolved was sprayed and granulated, and then dried with the same machine. The obtained granules were sieved and sized using a 16 mesh sieve.
- compound A 120 g
- mannitol 171.6 g
- crystalline cellulose 36 g
- HPC-L hydroxypropylcellulose
- the aqueous solution in which the solution was dissolved was sprayed and granulated, and then dried in the same machine.
- the obtained granules were sieved and sized using a 16 mesh sieve. Further, 282 g of this granule was taken, and croscarmellose sodium (Ac-D to Sol) (15 g) and magnesium stearate (3 g) were added thereto and mixed in a bag to obtain a mixed granule.
- This mixed granule was tableted to a weight of 30 Omg with a tableting machine using a 9.5 mm ⁇ punch to make an uncoated tablet.
- a film coating solution consisting of hydroxypropylmethylcellulose (19.6 g), polyethylene glycol 6000 (4 g), titanium oxide (2 g), and yellow iron sesquioxide (0.4 g) is applied to the resulting tablets in a pan-type coating machine (High coater, Freund Was sprayed to obtain film-coated tablets. At this time, the conditions were controlled so that the product temperature was 30 ° C to 50 ° C.
- Control Example 1 is a tablet containing no surface modifier and no acid or base.
- Control Example 2 is a tablet containing succinic anhydride with no surface modifier.
- Example 1 is a tablet containing light and anhydrous citrate as surface modifiers.
- Example 2 is a tablet which contains light caustic anhydride, which is a surface modifier, and succinic anhydride, and is obtained by surface-treating compound A and succinic anhydride with light caustic anhydride.
- poor fluidity was observed in the fluidized bed granulator, and it was found that the productivity was poor.
- These tablets were subjected to a disintegration test, a dissolution test, and a stability test. The disintegration test was performed according to the JP disintegration test method.
- Table 1 shows the results of the disintegration test. As is apparent from this surface force, the preparation of Control Example 1 did not completely disintegrate. For the preparation of Control Example 2, it took 30 minutes or more to disintegrate. On the other hand, the preparation of Example 1 was excellent in disintegration, and the preparation of Example 2 was further excellent in disintegration.
- As the test solution 900 ml of 0.1% cetyltrimethylammonium bromide-containing disintegration test method first solution (pH 1) was used.
- Figure 1 shows the results of the dissolution test.
- the preparation of Control Example 2 has a slow elution ability.
- the preparation of Example 1 has excellent dissolution of the active ingredient, and the preparation of Example 2 has further excellent dissolution of the active ingredient. It was.
- UV absorptiometer (measurement wavelength: 242 nm)
- This mixed granule was tableted to a weight of 600 mg with a tableting machine using a 13.5 mm ⁇ 8.5 mm ⁇ oblong type punch to make an uncoated tablet.
- the resulting tablet is coated with hydroxypropylmethylcellulose (139g), polyethylene glycol 6000 (32g), titanium oxide (16g), yellow ferric oxide (3g) film coating solution, pan-type coating machine (Driacoater, Purreck) Was sprayed to obtain film-coated tablets.
- the conditions were controlled so that the product temperature was 40 ° C-50 ° C.
- 5 mg tablets were prepared by adjusting Compound A and mannitol content.
- the disintegration property of the said solid formulation can be improved in the solid formulation containing the medicinal component which is easy to gelatinize.
- the productivity of the said solid formulation can be improved in the solid formulation which improved the disintegration property of the solid formulation.
- the stability of the said solid formulation can be improved in the solid formulation which improved the disintegration property of the solid formulation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05811622A EP1825866A4 (en) | 2004-12-03 | 2005-12-02 | SOLID PREPARATION |
US11/667,517 US20080031942A1 (en) | 2004-12-03 | 2005-12-02 | Solid Preparation |
JP2006546646A JPWO2006059716A1 (ja) | 2004-12-03 | 2005-12-02 | 固形製剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004350972 | 2004-12-03 | ||
JP2004-350972 | 2004-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006059716A1 true WO2006059716A1 (ja) | 2006-06-08 |
Family
ID=36565148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/022187 WO2006059716A1 (ja) | 2004-12-03 | 2005-12-02 | 固形製剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080031942A1 (ja) |
EP (1) | EP1825866A4 (ja) |
JP (1) | JPWO2006059716A1 (ja) |
WO (1) | WO2006059716A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010038689A1 (ja) * | 2008-09-30 | 2010-04-08 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
WO2013145750A1 (ja) * | 2012-03-29 | 2013-10-03 | 杏林製薬株式会社 | カプセル製剤 |
WO2014174846A1 (ja) | 2013-04-25 | 2014-10-30 | 杏林製薬株式会社 | 固形医薬組成物 |
JP2015003904A (ja) * | 2013-05-21 | 2015-01-08 | ライオン株式会社 | 内服用コーティング錠剤 |
WO2016063544A1 (ja) * | 2014-10-23 | 2016-04-28 | 杏林製薬株式会社 | 固形医薬組成物 |
JP2016518452A (ja) * | 2013-05-15 | 2016-06-23 | トビラ セラピューティクス, インコーポレイテッド | セニクリビロック組成物並びにその製造及び使用方法 |
US9687453B2 (en) | 2013-04-25 | 2017-06-27 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2459172C (en) * | 2001-08-08 | 2011-07-05 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use thereof |
CN106488769A (zh) | 2014-03-21 | 2017-03-08 | 妥必徕疗治公司 | 用于治疗纤维化的赛尼克韦罗 |
WO2016040860A1 (en) | 2014-09-12 | 2016-03-17 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
CA2965473A1 (en) | 2014-10-23 | 2016-04-28 | Kyorin-Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
JP6716568B2 (ja) | 2014-12-23 | 2020-07-01 | トビラ セラピューティクス, インコーポレイテッド | セニクリビロックの製造方法及び関連類似体 |
CA2975445A1 (en) | 2015-02-10 | 2016-08-18 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of fibrosis |
US10407411B2 (en) | 2016-06-21 | 2019-09-10 | Tobira Therapeutics, Inc. | Purified cenicriviroc and purified intermediates for making cenicriviroc |
US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6229514A (ja) * | 1985-07-31 | 1987-02-07 | ツイマ ソシエテ アノニム | 医薬活性物質の遅延放出形粒状物及びその製造方法 |
JPH0977675A (ja) * | 1995-09-18 | 1997-03-25 | Bayer Yakuhin Kk | 生薬配合発泡錠 |
JPH09509669A (ja) * | 1994-03-01 | 1997-09-30 | ゲルゲリイ、ゲルハルト | 発泡系及び製剤学的活性物質を含む顆粒状生成物又は錠剤並びにその調整方法 |
JPH10218762A (ja) * | 1996-12-03 | 1998-08-18 | Schering Purau Kk | 放出制御型マトリックス錠及びその製造方法 |
WO2000061109A1 (fr) * | 1999-04-12 | 2000-10-19 | Shionogi & Co., Ltd. | Procede de production de composition medicamenteuse renfermant un compose medicamenteux hydrophobe basique |
WO2002024167A1 (fr) * | 2000-09-19 | 2002-03-28 | Daiichi Pharmaceutical Co., Ltd. | Composition medicinale |
WO2003055525A1 (fr) * | 2001-12-25 | 2003-07-10 | Takeda Chemical Industries, Ltd. | Preparations contenant un acide |
JP2003335776A (ja) * | 2001-08-08 | 2003-11-28 | Takeda Chem Ind Ltd | 二環性化合物、その製造法および用途 |
JP2004256531A (ja) * | 2003-02-07 | 2004-09-16 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および用途 |
WO2005000312A1 (ja) * | 2003-06-27 | 2005-01-06 | Otsuka Pharmaceutical Co., Ltd. | 薬物徐放性粒子及びその製法 |
WO2005116013A1 (ja) * | 2004-05-28 | 2005-12-08 | Takeda Pharmaceutical Company Limited | 医薬化合物の結晶 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112779A (en) * | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
CA2353635A1 (en) * | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
RU2155038C1 (ru) * | 2000-01-27 | 2000-08-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения |
JP4443834B2 (ja) * | 2003-01-24 | 2010-03-31 | 杏林製薬株式会社 | 徐放性錠剤およびその製造方法 |
WO2004069834A1 (ja) * | 2003-02-07 | 2004-08-19 | Takeda Pharmaceutical Company Limited | 三環性化合物、その製造方法および用途 |
JP2005198025A (ja) * | 2004-01-07 | 2005-07-21 | Dainippon Screen Mfg Co Ltd | カラープロファイルの修正方法 |
WO2005089716A1 (ja) * | 2004-03-24 | 2005-09-29 | Takeda Pharmaceutical Company Limited | 高含量化製剤 |
ES2425937T3 (es) * | 2004-03-24 | 2013-10-18 | Takeda Pharmaceutical Company Limited | Estabilizante de emulsión |
-
2005
- 2005-12-02 JP JP2006546646A patent/JPWO2006059716A1/ja not_active Withdrawn
- 2005-12-02 US US11/667,517 patent/US20080031942A1/en not_active Abandoned
- 2005-12-02 EP EP05811622A patent/EP1825866A4/en not_active Withdrawn
- 2005-12-02 WO PCT/JP2005/022187 patent/WO2006059716A1/ja active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6229514A (ja) * | 1985-07-31 | 1987-02-07 | ツイマ ソシエテ アノニム | 医薬活性物質の遅延放出形粒状物及びその製造方法 |
JPH09509669A (ja) * | 1994-03-01 | 1997-09-30 | ゲルゲリイ、ゲルハルト | 発泡系及び製剤学的活性物質を含む顆粒状生成物又は錠剤並びにその調整方法 |
JPH0977675A (ja) * | 1995-09-18 | 1997-03-25 | Bayer Yakuhin Kk | 生薬配合発泡錠 |
JPH10218762A (ja) * | 1996-12-03 | 1998-08-18 | Schering Purau Kk | 放出制御型マトリックス錠及びその製造方法 |
WO2000061109A1 (fr) * | 1999-04-12 | 2000-10-19 | Shionogi & Co., Ltd. | Procede de production de composition medicamenteuse renfermant un compose medicamenteux hydrophobe basique |
WO2002024167A1 (fr) * | 2000-09-19 | 2002-03-28 | Daiichi Pharmaceutical Co., Ltd. | Composition medicinale |
JP2003335776A (ja) * | 2001-08-08 | 2003-11-28 | Takeda Chem Ind Ltd | 二環性化合物、その製造法および用途 |
WO2003055525A1 (fr) * | 2001-12-25 | 2003-07-10 | Takeda Chemical Industries, Ltd. | Preparations contenant un acide |
JP2004256531A (ja) * | 2003-02-07 | 2004-09-16 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および用途 |
WO2005000312A1 (ja) * | 2003-06-27 | 2005-01-06 | Otsuka Pharmaceutical Co., Ltd. | 薬物徐放性粒子及びその製法 |
WO2005116013A1 (ja) * | 2004-05-28 | 2005-12-08 | Takeda Pharmaceutical Company Limited | 医薬化合物の結晶 |
Non-Patent Citations (3)
Title |
---|
JAPAN PHARMACEUTICAL EXCIPIENTS COUNCIL: "Iyakuhin Tenkabutsu Jiten", 14 January 1994, KABUSHIKI KAISHA YAKUJI NIPPOSHA, pages: 132, XP002999422 * |
KATO Y. ET AL: "Hyomen Kaihitsuho o Mochiita Sokuhokaigata Jozai no Kaihatsu", NIPPON YAKUGAKUKAI NENKAI KOEN YOSHISHU, vol. 121, no. 3, 2001, pages 103 - 29UPE]I-136, XP002999423 * |
See also references of EP1825866A4 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010038689A1 (ja) * | 2008-09-30 | 2010-04-08 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
JP4582263B2 (ja) * | 2008-09-30 | 2010-11-17 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
CN102170885A (zh) * | 2008-09-30 | 2011-08-31 | 安斯泰来制药株式会社 | 口服用药物组合物 |
JPWO2010038689A1 (ja) * | 2008-09-30 | 2012-03-01 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
WO2013145750A1 (ja) * | 2012-03-29 | 2013-10-03 | 杏林製薬株式会社 | カプセル製剤 |
US9603804B2 (en) | 2013-04-25 | 2017-03-28 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
WO2014174846A1 (ja) | 2013-04-25 | 2014-10-30 | 杏林製薬株式会社 | 固形医薬組成物 |
US9687453B2 (en) | 2013-04-25 | 2017-06-27 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
JP2016518452A (ja) * | 2013-05-15 | 2016-06-23 | トビラ セラピューティクス, インコーポレイテッド | セニクリビロック組成物並びにその製造及び使用方法 |
JP2015003904A (ja) * | 2013-05-21 | 2015-01-08 | ライオン株式会社 | 内服用コーティング錠剤 |
WO2016063544A1 (ja) * | 2014-10-23 | 2016-04-28 | 杏林製薬株式会社 | 固形医薬組成物 |
JPWO2016063544A1 (ja) * | 2014-10-23 | 2017-08-03 | 杏林製薬株式会社 | 固形医薬組成物 |
JP2020079319A (ja) * | 2014-10-23 | 2020-05-28 | 杏林製薬株式会社 | 固形医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20080031942A1 (en) | 2008-02-07 |
EP1825866A1 (en) | 2007-08-29 |
EP1825866A4 (en) | 2008-03-12 |
JPWO2006059716A1 (ja) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006059716A1 (ja) | 固形製剤 | |
EP1949902B1 (en) | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | |
ES2381056T3 (es) | Preparación sólida estable que contiene un derivado de 4,5-epoximorfinano | |
KR101682963B1 (ko) | 4,5-에폭시모르피난 유도체를 함유하는 안정한 정제 | |
JP2003521447A (ja) | (3s)テトラヒドロ−3−フラニル(1s,2r)−3−[[(4−アミノフェニル)スルホニル](イソブチル)アミノ]−1−ベンジル−2−(ホスホノオキシ)プロピルカルバミン酸カルシウム | |
JPWO2008143240A1 (ja) | 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法 | |
SG191964A1 (en) | Orally dispersible tablet | |
KR102323255B1 (ko) | 의약 조성물 | |
CN101616905B (zh) | 苯并呋喃杀寄生物剂 | |
TWI756177B (zh) | 安定的經口投予用醫藥組成物 | |
US8163747B2 (en) | Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms | |
ES2704065T3 (es) | Preparaciones sólidas que comprenden tofogliflozina y método para su producción | |
KR20120098878A (ko) | 용출 안정성 제제 | |
JP2011105694A (ja) | オロパタジン経口固形組成物 | |
KR102022694B1 (ko) | 약학 조성물 | |
JPWO2016175230A1 (ja) | 経口投与用医薬組成物 | |
JP2020528912A (ja) | シチシン塩、シチシン塩の溶媒和物または水和物、シチシン塩の製造方法、医薬組成物、および治療方法 | |
KR20150115334A (ko) | 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형 | |
JP2023551145A (ja) | 医薬化合物の錯化剤塩製剤 | |
JP2007186450A (ja) | 塩酸パロキセチン含有製剤およびその製造方法 | |
CN106995410A (zh) | 一种内酰胺类衍生物及其应用 | |
JP2019089822A (ja) | トピロキソスタットの新規結晶形及びその製造方法 | |
WO2018079570A1 (ja) | 安定な医薬組成物 | |
KR20120011158A (ko) | 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 | |
RU2403045C2 (ru) | Способ изготовления антидепрессивного лекарственного препарата в форме таблеток на основе миансерина гидрохлорида, препарат, полученный этим способом, и его кристаллическая структура |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11667517 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006546646 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005811622 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005811622 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11667517 Country of ref document: US |